27th Annual Meeting

25th-27th May 2017
Budapest, Hungary

Danubius Health Spa Resort
Margitsziget****
H-1007 Budapest, Margitsziget
PROGRAMME
ABOUT EASDec
EASDec - EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES
Eye Complications Study Group (EASDec)
EASDec is a Study Group of the European Association for the Study of Diabetes (EASD) with special responsibility for the study of the eye complications of diabetes.
Its aim is to promote the advancement of knowledge of all aspects of diabetic retinopathy, including epidemiology, pathology, pathophysiology, investigation and treatment through active collaboration between ophthalmologists and diabetologists.
The ultimate goal of the Group is to prevent the development of diabetic retinopathy and to search for the best treatment of this condition in people with diabetes.

Meeting Chair
Professor Andrea Facsko, Hungary - President of the Hungarian Ophthalmological Society

EASDec board members
Scientific Program & Organising Committee
Professor Simon Harding, Liverpool, UK – President
Professor Rafael Simo, Barcelona, Spain – Vice President
Professor Tunde Peto, London, UK – Treasurer
Professor Reinier Schlingemann, Amsterdam, Netherlands – Secretary
Professor Massimo Porta, Turin, Italy – Past President

GENERAL INFORMATION
WEBSITE FOR FURTHER INFORMATION
www.easdec.org

Opening hours of registration
25 May, Thursday 15:00 - 18:30
26 May, Friday 08:00 - 18:00
27 May, Saturday 08:30 - 13:30
Opening hours of the exhibition

25 May, Thursday  16:00 - 18:00
26 May, Friday   09:00 - 18:00
27 May, Saturday 09:00 - 13:00

OFFICIAL LANGUAGE
English
No simultaneous translation will be provided.

LIABILITY
The Local Organising Committee and the Expert-Quality Congress and Travel Agency do not accept liability for personal medical expenses, travel expenses, losses of whatever nature incurred by delegates and/or accompanying persons.

INFORMATION
At the registration desk every staff member will be glad to help you with any enquiries.

LUNCHES
The registration fee does not include lunch for the registered participants on 25th and 27th of May.

REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>Late / On-site fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard</td>
<td>340 €</td>
</tr>
<tr>
<td>Resident, Student, Trainee*</td>
<td>240 €</td>
</tr>
<tr>
<td>Guest</td>
<td>90 €</td>
</tr>
</tbody>
</table>

*please contact EASDec before registering

Registration fee for regular participants and students includes
• Access to scientific presentations, program book and conference material
• Access to exhibition
• Opening ceremony
• Conference dinner
• Lunch – 26th May, 2017
• Coffee breaks
The organisers are grateful for the support of the sponsors and participation of the exhibitors at the congress.

GUIDELINE FOR SPEAKERS

1. Please locate your session room to arrive there at least 20 minutes before the start of the session and deliver the presentation to the technician. Presentation format: Microsoft PowerPoint, Microsoft Office Windows 10 and Office 2013 program. Electronic Support: USB only. Videos should be included in your PowerPoint. Presentation should be in a format that is supported by Windows Media Player.

2. Speakers should keep their presentations to the given time limits and will be asked by session moderators to move to their concluding slide if they overrun.

3. In case of using your own laptop, please inform the team in the Session/Lecture Room, at least 20 minutes before the start of the session, in order to prepare for this.
INSTRUCTIONS FOR POSTER PREPARATION
Posters must be brought to the Conference by the presenting author and should not be mailed in advance. The required dimensions are 90 cm (width) by 120 cm (height). At the top of the poster, please provide the title, names of the authors and their affiliations, all in bold lettering of about 2.5 to 3 cm size. Artwork and lettering should be large and clear enough so that the poster is readable from a distance of 1.5 m.

The organisers will not accept any responsibility for the collection or delivery / return of posters. Any posters left behind at the end of the meeting will be disposed of by the local organisers.

SOCIAL PROGRAMMES

Opening ceremony 25 May 2017, 18:30
Venue: Danubius Health Spa Resort Margitsziget****
Included in the registration fee.
Dress code: Smart casual

Conference reception & dinner 26 May 2017, 19:00
Venue: Europa Boat
Meet at reception of Danubius Health Spa Resort Margitsziget, Budapest
Included in the registration fee.
Dress code: Smart casual (do bring a jacket as it can be windy on the river)

Congress Organiser
Expert-Quality Congress and Travel Agency
H-1052 Budapest, Kigyó útca 4-6.
Information: Alexandra Szalma
Tel.: 00 36 1 311 66 87 Fax: 00 36 1 383 79 18
E-mail: congress@eqcongress.hu; Website: www.eqcongress.hu
15:00  Registration

16:45  SYMPOSIUM
LATE COMPLICATIONS OF DIABETIC EYE DISEASE

16:45  Welcome and introductions
Chaired by: Associate Professor Tamas Varkonyi and Professor Andrea Facsko

17:00  Associate Professor Tamas Varkonyi, Hungary
The diabetologist's view: treating diabetes in people with late complications

17:15  Professor Reinier Schlingemann, Netherlands
Diabetic macular oedema: treatment paradigms for chronic presentation

17:30  Associate Professor Miklos Resch, Hungary
Advanced diabetic retinopathy

17:45  Professor Zsolt Biro, Hungary
The diabetic cataract: when to operate?

18:00  Summary and meeting close

The official programme of EASDec starts

18.30-20.00  OPENING CEREMONY with light refreshments and finger food
Opened by Professors Andrea Facsko and Simon Harding
09.00  INTRODUCTION AND WELCOME  
Professor Simon Harding, UK

SESSION 1.  
NEW APPROACHES FOR TREATING DIABETIC RETINOPATHY  
Chaired by: Professors Rafael Simo and Jakob Grauslund

09.15  Hernández, C (Spain)  
Topical administration of dipeptidyl peptidase iv (DPP-IV) inhibitors prevents retinal neurodegeneration in experimental diabetes

09.30  Canning, P (Ireland)  
Neuroprotective efficacy of ARA290, an erythropoietin derived peptide, in diabetic retinopathy

09.45  Beltramo, E (Italy)  
Diabetic-like conditions modulate the expression of thiamine transporters in human retinal cells

10.00  Hu, TT (Belgium)  
Targeting placental growth factor attenuates retinal permeability and inflammation in diabetic Akimba mice

10.15  Weksler-Zangen, S (Israel)  
The Cohen diabetic rat an in-vivo model of diabetic retinopathy

10:30  Vilà-González, M (UK)  
Functional human IPS-ECS from diabetic patients provide a basis for in vitro modelling of diabetic retinopathy

10.45  Coffee/Tea Break

SESSION 2.  
NEURODEGENERATION AND BIOMARKERS  
Chaired by: Professor Jose Cunha-Vaz and Dr. Ingeborg Klaassen

11.25  Simó, R (Spain)  
Topical administration of somatostatin and brimonidine in the early stages of diabetic retinopathy: results of the Eurocondor study
11.50 Costa, M (Portugal)
Retinal layer location of increased retinal thickness and retinal thinning on the cohort of the Eurocondor clinical trial

12.05 Csutak, A (Hungary)
Two-years follow up of corneal microstructural changes in patients with Type 1 diabetes mellitus

12.20 Ecsedy, M, E (Hungary)
Variant SDF1-3'(801)A carriers are an increased risk for diabetic maculopathy

12.35 Cunha-Vaz, J (Portugal)
Diabetic retinopathy phenotypes of progression to macular oedema. Pooled analysis from independent longitudinal studies of up to two years duration

12.50 Lunch (poster presenters have priority)

SESSION 3.
POSTER SESSION

13.30-15.30

13.30-14.30 Poster presenters at poster, as moderators will visit
14.30 Tea/coffee served as poster presenters circulate

INVESTIGATION AND IMAGING
Moderated by: Associate Professor Andrea Csutak and Dr Vivian Schreur

1. Blindbæk, S (Denmark)
Changes in retinal oxygen saturation after intravitreal aflibercept in patients with diabetic macular oedema

2. Deák, K (Hungary)
Electrophysiological methods for the detection of subclinical stage retinal and optic nerve involvement in diabetes

3. Horváth, H (Hungary)
Choroidal thickness and diabetic retinopathy assessed by swept-source optical coherence tomography in patients with diabetes

4. Santos, A (Portugal)
OCT-leakage for quantification and location of fluid in diabetic macular oedema: response to anti-VEGF treatment
5. **Neves, C (Portugal)**
   Quantification of retinal microvascular density in diabetic patients using Cirrus Angioplex optical coherence tomography angiography (OCT-A)

6. **Lattanzio, R (Italy)**
   Preclinical retinopathy in type 1 diabetes mellitus: screening in paediatric age

7. **Szalay, L (Hungary)**
   Early detection of diabetic angiopathy based on the automated analysis of the Optovue RTVue XR 100 Avanti® angio-OCT recordings

**LABORATORY SCIENCE**

Moderated by: **Professors Cristina Hernandez and Paul Canning**

8. **Klaassen, I (Netherlands)**
   Identification of proteins associated with clinical and pathological features of proliferative diabetic retinopathy

9. **Huang, Y (Taiwan)**
   High expression of regulator of cell cycle (RGCC) protein in diabetic retinopathy

10. **Sergeys, J (Belgium)**
    Thorough longitudinal in vivo characterisation of the streptozotocin-induced diabetic mouse model

11. **Hajdú, R I (Hungary)**
    Detailed evaluation of suspected retinal ganglion cell degeneration in an animal model of type 2 diabetes mellitus

**EPIDEMIOLOGY AND RISK FACTORS**

Moderated by: **Dr. Amber van der Heijden and Dr. Gabor Toth**

12. **Pék, A (Hungary)**
    Cataract and diabetes coexistence based on a RAAB study in Hungary

13. **Tomić, M (Croatia)**
    Inflammation and obesity: possible link to the pathogenesis of retinopathy in type 2 but not in type 1 diabetes

14. **Diogo Ramos, J (Portugal)**
    RetmarkerDR computed MA formation rate as a predictor of DR progression to diabetic macular oedema. Pooled analysis from different longitudinal studies of up to two years duration

15. **Torp, T (Denmark)**
    Changes in retinal arterial geometry in relation to activity of proliferative diabetic retinopathy 6 months after panretinal photocoagulation
16. **Gooding, K (UK)**  
Examining longitudinal changes of macular thickness in the early stages of diabetic retinopathy  
17. **Blows, P (UK)**  
The next steps for the DR-NET: a network to tackle the burden of diabetic retinopathy in 13 low- and middle-income countries  

**SCREENING AND AUTOMATION**  
Moderated by: **Professor Frank Verbraak and Dr. Dorottya Szabo**  
18. **Antal, B (Hungary)**  
Data analysis applied to diabetic retinopathy screening: performance evaluation  
19. **Solanki, K (USA)**  
ETDRS 7-field stereoscopic reference standard for clinical validation of automated DR screening on 2-field monoscopic images  
20. **D'Souza, Y (UK)**  
The diabetic eye screening service goes green in Manchester, UK  
21. **Jones, C (UK)**  
Outcomes of referrals from diabetes eye screening to a slit lamp biomicroscopy clinic  
22. **Creer, R (UK)**  
The introduction of the diabetic passport within ophthalmology clinics at Manchester Royal Eye Hospital: Patient opinion and perceived benefits  
23. **Harding, S (UK)**  
Safety of individualised variable interval screening for referable diabetic retinopathy – baseline data from the ISDR randomised controlled study  
24. **Russell, G (USA)**  
Automated longitudinal analysis of retinal fundus images with applications to screening intervals and risk stratification  
25. **Ibanez-Bruron, M (UK)**  
How well integrated is the ophthalmic care for children and young people living with diabetes in England?  
26. **Scanlon, P (UK)**  
Diabetic retinopathy screening in China  

**CLINICAL PRACTICE**  
Moderated by: **Associate Professor Miklos Resch and Dr Morten B. Hansen**  
27. **Lopez Galvez, M (Spain)**  
Clinical practice in the management of diabetic macular oedema. Results
from a retinologists’ national survey

28. **Jasani, K (UK)**
A retrospective review of clinical outcomes of intravitreal aflibercept for diabetic macular oedema (DMO) in treatment naïve patients with those switched from alternative therapies over 12 months at Manchester Royal Eye Hospital (MREH)

29. **Ba-Ali, S (Denmark)**
Salivary melatonin concentrations in type-1 and type-2 diabetes mellitus

30. **Peto, T (UK)**
ILUVIEN (fluocinolone acetonide [FAc]) in the management of chronic diabetic macular oedema – assessing the need for additional therapies in clinical practice

**SESSION 4**
Chairred by: **Professors Simon Harding and Andrea Facsko**

15.30 **Gábor Tóth, (Hungary)**
*Winner of the best young investigator abstract from Hungary*
Diabetes and diabetic retinopathy in people aged 50 and older in Hungary

15.45 **Morten B. Hansen (UK)**
Diabetic retinopathy in Europe – results of the E3 Consortium Diabetes Group

16:00 **EVA KOHNER LECTURE**
*Steve Aldington: "I've looked at life from both sides now"*
Introduced by **Professor Simon Harding**

16.45 **ANNUAL GENERAL MEETING**
Moderator: **Professor Reinier Schlingemann**

19.00 **CONFERENCE RECEPTION AND DINNER**
Meet at reception of Danubius Health Spa Resort Margitsziget

---

**Saturday 27th May 2016**

08.30 Registration
SESSION 5.
EARLY DETECTION AND TECHNOLOGY IN SCREENING
Chaired by: Professors Tunde Peto and Steve Aldington

09.00 Verbraak, F (Netherlands)
Real life evidence of improved automated detection of diabetic retinopathy through integration of deep learning

09.15 Van der Heijden, A (Netherlands)
Prediction models for the risk of retinopathy in people with type 2 diabetes. A systematic review

09.30 Stratton, I (UK)
Uptake of diabetic eye screening - are some domains of deprivation more important than others?

09.45 Szabo, D (Hungary)
Telemedical diabetic retinopathy screening in Hungary

10.00 Dupas, B (France)
Decreased macular flow density is associated with visual impairment in patients with florid diabetic retinopathy

10.30 Coffee/Tea Break

SESSION 6.
DIABETES INDUCED RETINAL INFLAMMATION
Chaired by: Professors Reinier Schlingemann and Frank Verbraak

11.10 KEYNOTE LECTURE: Professor Andrea Facsko (Hungary)
Treating advanced diabetic eye disease

11.30 10 minutes discussion

11.40 Tecilazich, F (USA)
Patroller Monocytes protect retinal microvessels from diabetes

11.55 Solà-Adell, C (Spain)
Calcium dobesilate prevents the oxidative stress and inflammation induced by diabetes in the retina of db/db mice

12.10 Van der Wijk, A (Netherlands)
Corticosteroids induce barrier properties of the blood-retinal barrier via direct effects on the endothelium

12.25 Mazzeo, A (Italy)
Somatostatin protects human retinal pericytes from microglia-mediated
inflammation

12.40  **Schreur, V (Netherlands)**

*The winner of the Professor Anne Katrin Sjolie Prize for the best abstract from a trainee*

Hyperreflective foci predict treatment response to bevacizumab in patients with diabetic macular oedema

**13.00  BEST POSTER PRIZE CEREMONY AND CLOSING REMARKS**

Professor Simon Harding, UK